Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Mann

Showing results (1031-1040 of 1,096) with videos related to

Pageof 110
Sort By:
American Heart Journal|November 2, 2013
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trialSteven P Marso, Neil R Poulter, Steven E Nissen, et al.
Oral Oncology|December 12, 2018
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell linesMegan L Ludwig, Aditi Kulkarni, Andrew C Birkeland, et al.
Kidney International|May 26, 2020
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathyThomas Rauen, Stephanie Wied, Christina Fitzner, et al.
PNAS Nexus|April 3, 2024
Earth at risk: An urgent call to end the age of destruction and forge a just and sustainable futureCharles Fletcher, William J Ripple, Thomas Newsome, et al.
Kidney International|April 24, 2019
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceAlfred K Cheung, Tara I Chang, William C Cushman, et al.
Journal of Substance Abuse Treatment|August 22, 2018
Evaluating moderators of beneficial effects of severity-based assignment to substance use treatments in impaired driversChristine M Wickens, Rosely Flam-Zalcman, Robert E Mann, et al.
The New England Journal of Medicine|June 14, 2016
Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesSteven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW TrialKatherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Pageof 110

Showing results (1031-1040 of 1,096) with videos related to

Sort By:
Pageof 110
American Heart Journal|November 2, 2013
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trialSteven P Marso, Neil R Poulter, Steven E Nissen, et al.
Oral Oncology|December 12, 2018
The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell linesMegan L Ludwig, Aditi Kulkarni, Andrew C Birkeland, et al.
Kidney International|May 26, 2020
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathyThomas Rauen, Stephanie Wied, Christina Fitzner, et al.
PNAS Nexus|April 3, 2024
Earth at risk: An urgent call to end the age of destruction and forge a just and sustainable futureCharles Fletcher, William J Ripple, Thomas Newsome, et al.
Kidney International|April 24, 2019
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceAlfred K Cheung, Tara I Chang, William C Cushman, et al.
Journal of Substance Abuse Treatment|August 22, 2018
Evaluating moderators of beneficial effects of severity-based assignment to substance use treatments in impaired driversChristine M Wickens, Rosely Flam-Zalcman, Robert E Mann, et al.
The New England Journal of Medicine|June 14, 2016
Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesSteven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, et al.
The New England Journal of Medicine|September 24, 2020
Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 18, 2026
Kidney and Survival Outcomes with Semaglutide by Chronic Kidney Disease Severity in the FLOW TrialKatherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer, et al.
Journal of the American College of Cardiology|September 1, 2024
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW TrialRichard E Pratley, Katherine R Tuttle, Peter Rossing, et al.
Pageof 110